AOD-9604 is a modified fragment of human growth hormone developed around fat-metabolism hypotheses. Reddit discussions frequently describe it as a targeted option for stubborn fat, sometimes in a stack with semaglutide, tirzepatide, retatrutide, CJC products, or intensive dieting.
That stacking pattern makes the weakest measurement look persuasive. A small drop in smart-scale body-fat percentage can come from hydration, glycogen, food intake, or device error. When calorie intake and a potent weight-management drug also change, AOD-9604 cannot be isolated.
What Reddit reports look like
Positive posts often describe a small change in waist, visual leanness, or a scale’s body-fat estimate rather than a dramatic fall in body weight. Some users say a particular area looks leaner. Many others report no detectable effect and question whether the peptide adds anything to diet or another medication.
Side-effect reports are less consistent than with GLP-1 drugs but include headache, fatigue, injection-site reactions, or nonspecific symptoms. Low symptom burden does not establish purity, sterility, or long-term safety.
What the preclinical evidence can tell us
Animal studies evaluated growth-hormone fragments and reported effects on fat oxidation, lipolysis, or weight in obese mice. Those studies help explain the development rationale. They do not demonstrate meaningful fat loss in free-living humans or validate products currently sold online.
FDA advisory materials reviewed AOD-9604 for compounding and described limited evidence, including a lack of persuasive effectiveness data for obesity. The agency proposed that it not be included on the 503A Bulks List.
Measure fat loss with more than a smart scale
Bioimpedance estimates are strongly affected by hydration, meal timing, exercise, and device algorithms. Use weight trends, waist measurements, standardized photos, and clinically appropriate methods together.
Why “stubborn fat” is hard to test
Spot reduction is a tempting interpretation when one body area appears to change first. Fat distribution, lighting, posture, bloating, and measurement placement can create that impression. A claim of regional fat loss requires more than a mirror or tape measure taken at different times of day.
Weight-management outcomes also need enough time to distinguish signal from ordinary fluctuation. A rapid short-term change is more likely to contain water and glycogen than pure fat mass.
A stronger way to audit a claim
- Use a seven-day weight average and a consistently placed waist measurement.
- Record calories, protein, sodium, menstrual cycle, training, and bowel changes.
- List all GLP-1 drugs, stimulants, hormones, and other peptides.
- Predefine the smallest change that would matter and a time window long enough to observe it.
- Report no effect as clearly as a positive change.
How to make your tracking more useful
Strong personal logs begin with a short baseline and keep the same measurements long enough for a pattern to emerge. Peptify can connect dates, context, and observations locally on your device so the record is more useful than memory alone.
- Seven-day average weight, waist at a fixed landmark, and standardized photos if desired.
- Calories, protein, sodium, activity, resistance training, and concurrent weight-management medication.
- Headache, fatigue, injection-site reactions, and any clinically significant metabolic symptoms.
See the N-of-1 tracking guide and visual tracking guide for a reproducible setup.
Questions to discuss with a healthcare practitioner
- Is there an approved, evidence-based weight-management approach that better matches the goal and medical history?
- Could endocrine disease, medication effects, sleep apnea, or fluid changes be influencing weight or body composition?
- What evidence supports the exact product and route, and what safety information is missing?